Duopharma eyes 10% revenue growth


The higher target for 2024 would be driven by both public and export portfolios.

KUALA LUMPUR: Duopharma Biotech Bhd aims for a 10% revenue growth this year, up from RM704.73mil achieved in the financial year ended Dec 31, 2023.

Group managing director Leonard Ariff Abdul Shatar said the higher target for 2024 would be driven by both public and export portfolios.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Ringgit likely to trade cautiously next week ahead of key US data
Watts from water
Singapore’s financial sector a big winner
Up in Arms - or up the value chain?
Asia bonds for diversification
Smart city can’t beat the traffic
Powering a new reinvestment cycle as demand surges
AI disruption fears rock markets
Private equity hits a sixer
Dubai luxe property keeps booming

Others Also Read